Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 2,904 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Completed Phase 2 Interventional Results available

Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients

NCT00420771
View directory record Official record
Conditions
Benzodiazepine Dependence, Opioid Dependence
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Long Island City, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 4 Interventional Results available

Evaluation Exparel Delivered in Knee Replacement

NCT02011464
View directory record Official record
Conditions
Arthritis
Interventions
Exparel, Saline
Drug · Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of HPG1860 in Subjects With NASH

NCT05338034
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HPG1860, Placebo
Drug
Lead sponsor
Hepagene (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Texas City, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

NCT01928381
View directory record Official record
Conditions
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Interventions
AZD5213 + pregabalin, Placebo, pregabalin capsules
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • Newnan, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2016 · Synced Oct 30, 2026, 6:14 PM EDT
Recruiting Phase 2 Interventional

The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)

NCT05562167
View directory record Official record
Conditions
Heart Failure
Interventions
KNO3, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years to 79 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

NCT01915901
View directory record Official record
Conditions
Healthy
Interventions
bismuth subsalicylate (Pepto-Bismol®), matching placebo (bismuth subsalicylate), dimethyl fumarate (DMF)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Renal PK Study of LC350189

NCT04066712
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
LC350189 200 mg
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Potassium Citrate on Bone Metabolism

NCT00357331
View directory record Official record
Conditions
Bone Diseases, Metabolic, Osteoporosis, Postmenopausal
Interventions
potassium citrate
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 75 Years · Female only
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder

NCT04753164
View directory record Official record
Conditions
Binge-Eating Disorder
Interventions
ACT-539313, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
30
States / cities
Beverly Hills, California • Encino, California • Garden Grove, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)

NCT06619665
View directory record Official record
Conditions
Healthy, Narcolepsy
Interventions
MK-6552, MK-6552 placebo, Modafinil, Modafinil placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Atlanta, Georgia • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis

NCT04303195
View directory record Official record
Conditions
Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions
NG101, Placebo
Drug
Lead sponsor
Neurogastrx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
83
States / cities
Dothan, Alabama • Foley, Alabama • Mobile, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis

NCT01113034
View directory record Official record
Conditions
Asthma, Bronchiectasis
Interventions
DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra)
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

NCT03926611
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064 Arm 1, LOU064 Arm 2, LOU064 Arm 3, LOU064 Arm 4, LOU064 Arm 5, LOU064 Arm 6, Placebo arm
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
11
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 30, 2026, 6:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

NCT06087653
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Lenalidomide 25 MG Oral Capsule
Drug
Lead sponsor
Starton Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Wilson, North Carolina • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)

NCT02253745
View directory record Official record
Conditions
ADHD
Interventions
V81444, Placebo
Drug
Lead sponsor
Vernalis (R&D) Ltd
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

NCT03569475
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Fluoxetine, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
7 Years to 17 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
51
States / cities
Little Rock, Arkansas • Beverly Hills, California • Corona, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 30, 2026, 6:14 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

NCT04777357
View directory record Official record
Conditions
Depression, Bipolar I Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
10 Years to 17 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
69
States / cities
Bentonville, Arkansas • Anaheim, California • Beverly Hills, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 1Phase 2 Interventional

The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program

NCT02431728
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
Melatonin, Matched Placebo
Dietary Supplement
Lead sponsor
Duquesne University
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Tyrosol and Creatine on Endurance, Strength, and Fatigue Resistance in Healthy Adults

NCT06883292
View directory record Official record
Conditions
Tyrosol, Creatine, Endurance Performance, Cognition
Interventions
Tyrosol, Creatine, Resistant Dextrin
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 30, 2026, 6:14 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

NCT03551522
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Seladelpar, Placebos
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Glendale, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Effect of BIBW 2948 BS in COPD

NCT00423137
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions
BIBW 2948 BS, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 30, 2026, 6:14 PM EDT
Enrolling by invitation Early Phase 1 Interventional

Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder

NCT04509102
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Adderall-XR, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

Modafinil - Escitalopram Study for Cocaine Dependence

NCT01601730
View directory record Official record
Conditions
Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Substance Abuse
Interventions
Modafinil and Escitalopram, Placebo, Modafinil, Escitalopram
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 30, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)

NCT02700529
View directory record Official record
Conditions
Lymphedema
Interventions
ubenimex, placebo
Drug · Other
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Stanford, California • Orlando, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 30, 2026, 6:14 PM EDT